Biobase. Cc

Lab Reagents

Biobase Lab Instruments Laboratories manufactures the www. biobase. cc reagents distributed by Genprice. The Www. Biobase. Cc reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Biobase lab Instruments. Other Www. products are available in stock. Specificity: Www. Category: Biobase. Group: Cc

Cc information

CC-90003
B2419-5
EUR 414

CC-115
B2499-25
EUR 631

CC-115
B2499-5
EUR 196

darkroom 254/254nm
VLCN15-CC ea
EUR 1535

CC-115 (hydrochloride)
HY-16962A 10mM/1mL
EUR 216

CC-401 (hydrochloride)
HY-13022 10mg
EUR 422

CC-401 hydrochloride
A3287-10 10 mg
EUR 538
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-5 5 mg
EUR 321
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-5.1 10 mM (in 1mL DMSO)
EUR 348
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

CC-401 hydrochloride
A3287-50 50 mg
EUR 1497
Description: CC-401 is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential antineoplastic activity.

Lenalidomide (CC-5013)
A4211-100 100 mg
EUR 189
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-250 250 mg
EUR 224
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-5.1 10 mM (in 1mL DMSO)
EUR 113
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-50 50 mg
EUR 154
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-500 500 mg
EUR 258
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Lenalidomide (CC-5013)
A4211-S Evaluation Sample
EUR 81
Description: Lenalidomide (also known as CC-5013), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition, and direct antineoplastic effects.

Pomalidomide (CC-4047)
A4212-10 10 mg
EUR 142
Description: Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM).